Federal Supply Schedule 36F79720D0153
Award Date
7/15/20
Last Date to Order
4/1/26
Federal Agency
Veterans Integrated Service Network 12
Awardee
Xeris Pharmaceuticals, Inc.
Ultimate Awardee
Not listed
NAICS Category
325412 - Pharmaceutical Preparation Manufacturing
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Pricing Type
Fixed Price with Economic Price Adjustment
Legislative Mandate
Not listed
National Interest Action
None
Award Type
Multiple
Primary Consortia Member
Not listed
Similar IDVs
The National Acquisition Center of the Department of Veterans Affairs (VA) has awarded a single-award Blanket Purchase Agreement (BPA) to Xeris Pharmaceuticals, Inc. for the procurement of the pharmaceutical drug KEVEYIS. The BPA, valued at $661,240.80, has a period of performance from June 2022 to June 2024. KEVEYIS is used to treat hyperkalemic periodic paralysis, a rare genetic disorder. This BPA enables the VA to efficiently order KEVEYIS through established contract terms and pricing,...
The National Acquisition Center of the U.S. Department of Veterans Affairs (VA) has awarded a $32,500,000 Blanket Purchase Agreement (BPA) to Ardelyx, Inc., a pharmaceutical company, for the supply of XPHOZAH (tenapanor), a medication used to treat hyperphosphatemia in patients on dialysis. This single-award BPA, which has an ultimate completion date of April 29, 2026, allows VA medical centers nationwide to efficiently procure the XPHOZAH medication as needed through delivery orders. Ardelyx,...
Ardelyx, Inc., a for-profit pharmaceutical company, has been awarded multiple federal contract Indefinite Delivery Vehicles (IDVs) from the U.S. Department of Veterans Affairs (VA) to provide specialized pharmaceutical products, primarily the drug XPHOZAH (tenapanor), to support the healthcare needs of military veterans. The key contracts include a $32,500,000 Blanket Purchase Agreement (BPA) and a $300,000 Federal Supply Schedule (FSS-61-IB) contract, both of which enable Ardelyx to efficiently...
The Department of Veterans Affairs awarded a multiple-award federal supply schedule contract to Amryt Pharmaceuticals Inc. with a potential value of $225,000. The schedule is for pharmaceuticals and hematology-related products under contract number 65 IB. This enables ordering through September 2028. Additionally, the Department of Veterans Affairs National Acquisition Center awarded a single-award blanket purchase agreement to Amryt Pharmaceuticals with a value of up to $1,000,000. The BPA...
The Department of Veterans Affairs (VA) has awarded a $1,710,320.00 Federal Supply Schedule (FSS) contract to Amneal Pharmaceuticals of New York, LLC, a for-profit limited liability company, for the supply of drugs, pharmaceuticals, and hematology-related products. The contract has an ultimate completion date of June 30, 2027 and is not set-aside. Under this FSS contract, Amneal has received several firm fixed-price delivery order awards from the VA, totaling over $670,000, for the supply of...
The U.S. Department of Veterans Affairs (VA) has awarded a Federal Supply Schedule contract (FSS-61-IB) to UCB, Inc., a global biopharmaceutical company, for the procurement of pharmaceutical drugs and related products. The contract has a ceiling value of $625,636,910 and a period of performance through September 14, 2025. Under this contract, UCB, Inc. will supply a variety of pharmaceutical products to the VA, with a focus on drugs used to treat neurology and immunology disorders, such as...
The Department of Veterans Affairs National Acquisition Center awarded a Blanket Purchase Agreement (BPA) to Jazz Pharmaceuticals, Inc. for the delivery of specialty pharmaceutical products, primarily the sleep disorder medication Xyrem. The $150 million BPA is issued under Jazz Pharmaceuticals' Pharmaceuticals and Drugs Federal Supply Schedule (FSS) contract, allowing the VA to efficiently procure needed medications for its healthcare facilities. Four task orders worth up to $717,519 have...
The Department of Veterans Affairs (VA) awarded a Blanket Purchase Agreement (BPA) under the Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) to Jazz Pharmaceuticals, Inc., a global biopharmaceutical company, to provide specialty pharmaceutical products such as Xyrem, Xywav, and sodium oxybate formulations. The BPA, valued at up to $150 million, allows the VA to efficiently procure needed medications to support healthcare services for veterans at VA medical facilities nationwide....
The Department of Veterans Affairs Veterans Health Administration Veterans Integrated Service Network 12 awarded a Federal Supply Schedule contract to Tetraphase Pharmaceuticals Inc., a for-profit organization and subsidiary of La Jolla Pharmaceutical Company. The contract is for the procurement of DRUGS, PHARMACEUTICALS, & HEMATOLOGY RELATED PRODUCTS under the Pharmaceuticals and Drugs (FSS-61-IB) master schedule. The contract is a multiple-award, unrestricted (no set-aside) vehicle with...
The U.S. Department of Veterans Affairs (VA) National Acquisition Center awarded a single-award Blanket Purchase Agreement (BPA) to Takeda Pharmaceuticals America Inc. in July 2020. The $19,472,334.90 BPA, which falls under Takeda's General Services Administration (GSA) Pharmaceutical and Drugs Schedule contract, facilitates the streamlined procurement of critical specialty pharmaceutical products for the VA healthcare system. Key products under this BPA include CINRYZE and KALBITOR for...
Name | Description | Awardee | Potential Value (Click to sort descending) | Award Date (Click to sort descending) | Last Date To Order (Click to sort descending) | Updated At (Click to sort descending) |
|---|---|---|---|---|---|---|
36F79720D0153-36E79722A0022 | Xeris Pharmaceuticals, Inc. | $661.2k | 6/17/22 | 6/16/26 | 4/3/25 |